Results 11 to 20 of about 1,181,987 (277)
Faricimab Treat-and-Extend for Diabetic Macular Edema
OphthalmologyPurpose: To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab according to a personalized treat-andextend (T&E)-based regimen with up to every-16-week dosing in the YOSEMITE and RHINE (ClinicalTrials.govidentifiers, NCT03622580 and ...
WONG, T +2 more
exaly +4 more sources
A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration [PDF]
Frontiers in Medicine, 2022 PurposeTo compare the efficacy and safety of conbercept using a treat-and-extend (T&E) regimen vs. a pro re nata (PRN) regimen in Chinese patients with neovascular age-related macular degeneration (nAMD).MethodsThis was a randomized, multicenter, non-
Huixun Jia +22 more
doaj +2 more sources
Treat and Extend Regimen of Aflibercept in the Treatment of Type 1 Choroidal Neovascularization Secondary to Chronic Central Serous Chorioretinopathy: Three-year Follow-Up [PDF]
Clinical OphthalmologyTaras B Kustryn, Oleg S Zadorozhnyy, Illia O Nasinnyk, Alla O Nevska, Kseniia V Troianovska, Nataliya V Pasyechnikova, Andrii R Korol Laser Microsurgery Department, The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of ...
Kustryn TB +6 more
doaj +2 more sources
The effect of COVID-19 pandemic restrictions on neovascular AMD patients treated with treat-and-extend protocol [PDF]
International Ophthalmology, 2021 To investigate the adherence rate of neovascular age-related macular degeneration (nAMD) patients in treat-and-extend (TAE) protocol to their anti-vascular endothelial growth factor (anti-VEGF) intravitreal injection (IVI) appointments and to evaluate the functional and anatomical outcomes of the patients who attended and did not attend their IVI ...
Mehmet Orkun Sevik +4 more
openaire +3 more sources
Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration [PDF]
Ophthalmology, 2018 Rufino Silva +5 more
openaire +3 more sources
Frontiers in Medicine, 2021 The use of anti-vascular-endothelial growth factor agents for neovascular age-related macular degeneration (nAMD) in different treatment schemes is widely common in clinical practice.
Laura Hoffmann, Katja Hatz, Katja Hatz
doaj +1 more source
Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema [PDF]
Scientific Reports, 2020 AbstractThis study was performed to investigate the efficacy of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema (DME). This prospective, multicentre, interventional, single-arm, 104-week clinical trial included 48 patients with DME visual impairment.
Yu Cheol Kim +8 more
openaire +3 more sources
International Journal of Retina and Vitreous, 2021 Background To assess the morphological and functional outcome of intravitreal aflibercept following the treat and extend protocol compared to the fixed protocol for treatment of eyes with neovascular age-related macular degeneration.
Alaa Din Abdin +6 more
doaj +1 more source
BMC Ophthalmology, 2020 Background To evaluate the three-year outcome after intravitreal aflibercept injection (IAI) for neovascular age-related macular degeneration (nAMD). Methods Forty-nine treatment-naïve nAMD patients (50 eyes) were enrolled in this prospective study.
Kanako Itagaki +5 more
doaj +1 more source
International Journal of Retina and Vitreous, 2021 Purpose To investigate the visual and anatomical outcomes associated with treat-and-extend (TAE) regimen of intravitreal (IVT) aflibercept in eyes with treatment naïve neovascular age-related macular degeneration (nvAMD).
Mohamed Kamel Soliman +4 more
doaj +1 more source